Study of Novel Types 1 and 3 Oral Poliomyelitis Vaccines

Inclusion criteria

• ✓. Males or females, from 18 to 45 years of age (inclusive) at the time of enrollment
• ✓. Healthy, as defined by the absence of any clinically significant medical conditions, either acute or chronic, as determined by medical history, physical examination, screening laboratory test results, and clinical assessment of the investigator
• ✓. Willing and able to provide written informed consent prior to performance of any study-specific procedure
• ✓. If female and of childbearing potential\*, be not breastfeeding and not pregnant (based on a negative serum pregnancy test at screening and a negative urine pregnancy test during the 24 hours prior to any study vaccination), agreeing to have repeated pregnancy tests prior to any study vaccination, and having practiced adequate contraception\*\* for 30 days prior to first study vaccination and willing to continue using adequate contraception consistently for at least 90 days after the last study vaccination and until cessation of vaccine virus shedding is confirmed
• ✓. Resides in study area and is able and willing to adhere to all study restrictions and to all study visits and procedures (as evidenced by a signed informed consent form \[ICF\] and assessment by the investigator)
• ✓. Agrees not to and has no plans to travel outside the United States (US) until confirmation of cessation of vaccine virus shedding in stool at or after the study Day 57 stool collection
• ✓. Able and willing to be contacted by telephone or text, and willing for study staff to leave telephone voice or electronic messages as needed
• ✓. Neutralizing antibody titer ≥ 1:8 for poliovirus type 1 (for participants in cohorts 1 and 2) and ≥ 1:8 for poliovirus type 3 (for participants in cohorts 3 and 4)

Exclusion criteria